FGF Receptor 2 (D4H9) Rabbit mAb

• 产品编号：CST-11835S      品牌：CST       原厂货号：11835S
• 产品分类：抗体 > 一抗 > 蛋白特异性一抗
• 应用分类：

描述：

FGF Receptor 2 (D4H9)兔单抗能够识别内源性水平的总FGF受体2蛋白。该抗体不与其他FGF受体家族成员发生交叉反应。该单克隆抗体是通过用重组蛋白免疫动物而制备的，该重组蛋白是人FGF受体2蛋白羧基末端区域的残基。

成纤维细胞生长因子 (FGFs)通过细胞表面的酪氨酸激酶受体传递信号，对靶细胞产生促有丝分裂和血管生成的效应。已知FGF受体家族有四个成员：FGFR-1 (flg), FGFR-2 (bek, KGFR), FGFR-3和FGFR-4。每个受体都有一个胞外配体结合区、跨膜区和一个胞内激酶区（1）。在结合配体和二聚化之后，受体的特定的酪氨酸位点发生磷酸化（2）。在FGFR-1的羧基端有7个酪氨酸位点能被磷酸化：Tyr463, 583, 585, 653, 654, 730和 766。Tyr653 和Tyr654对激活的FGFR的催化活性十分重要，对信号传导也是必要的(3)。其它的磷酸化酪氨酸位点能够为下游信号分子，如Crk 和PLCγ，提供结合位点(4,5)。

FGFR2有一些剪接异构体，配体特异性主要是由选择性剪接的外显子8（IIIb）和9（IIIc）决定的。选择性剪接是细胞类型特异性的，从而导致亚型在各种组织中的分布和生物活性（6,7）。调查研究表明，在相应的FGFR2基因突变导致特点是面部及肢体的缺陷的综合征，包括拉德综合征，克鲁综合症，BEARE史蒂文森表皮Gyrata综合征，菲佛综合症，亚伯综合症和杰克逊 - 魏斯综合征（8-10）。调查还发现在胃，子宫内膜癌和乳腺癌中，FGFR2的突变和表达改变（11）。

1. Powers, C.J. et al. (2000) Endocr Relat Cancer 7, 165-97.
2. Reilly, J.F. et al. (2000) J Biol Chem 275, 7771-8.
3. Mohammadi, M. et al. (1996) Mol Cell Biol 16, 977-89.
4. Mohammadi, M. et al. (1991) Mol Cell Biol 11, 5068-78.
5. Larsson, H. et al. (1999) J Biol Chem 274, 25726-34.
6. Muh, S.J. et al. (2002) J Biol Chem 277, 50143-54.
7. Coutts, J.C. and Gallagher, J.T. (1995) Immunol Cell Biol 73, 584-9.
8. Jeftha, A. et al. (2004) J Clin Pediatr Dent 28, 173-6.
9. Wilkinson, C.C. et al. (2012) Childs Nerv Syst 28, 1221-6.
10. Slavotinek, A. et al. (2009) Am J Med Genet A 149A, 1814-7.
11. Katoh, M. (2009) J Invest Dermatol 129, 1861-7.

原厂资料：

Specificity / Sensitivity

FGF Receptor 2 (D4H9) Rabbit mAb recognizes endogenous levels of total FGF receptor 2 protein. This antibody does not cross-react with other FGF receptor family members.、

Source / Purification

Monoclonal antibody is produced by immunizing animals with a recombinant protein corresponding to residues near the carboxy terminal region of human FGF receptor 2 protein.

Background

Fibroblast growth factors (FGFs) produce mitogenic and angiogenic effects in target cells by signaling through cell surface receptor tyrosine kinases. There are four members of the FGF receptor family: FGFR1 (flg), FGFR2 (bek, KGFR), FGFR3, and FGFR4. Each receptor contains an extracellular ligand binding domain, a transmembrane domain, and a cytoplasmic kinase domain (1). Following ligand binding and dimerization, the receptors are phosphorylated at specific tyrosine residues (2). Seven tyrosine residues in the cytoplasmic tail of FGFR1 can be phosphorylated: Tyr463, 583, 585, 653, 654, 730, and 766. Tyr653 and Tyr654 are important for catalytic activity of activated FGFR and are essential for signaling (3). The other phosphorylated tyrosine residues may provide docking sites for downstream signaling components such as Crk and PLCγ (4,5).

FGFR2 has several splicing isoforms, with ligand specificity largely determined by alternative splicing of exons 8 (IIIb) and 9 (IIIc). Alternative splicing is cell type specific, resulting in isoforms showing various tissue distribution and biological activities (6,7). Research studies have shown that mutations in the corresponding FGFR2 gene cause syndromes characterized by facial and limb defects, including LADD Syndrome, Crouzon Syndrome, Beare-Stevenson Cutis Gyrata Syndrome, Pfeiffer Syndrome, Apert Syndrome, and Jackson-Weiss Syndrome (8-10). Investigators have also observed mutations and altered expression of FGFR2 in cases of gastric, endometrial, and breast cancer (11).

1. Powers, C.J. et al. (2000) Endocr Relat Cancer 7, 165-97.
2. Reilly, J.F. et al. (2000) J Biol Chem 275, 7771-8.
3. Mohammadi, M. et al. (1996) Mol Cell Biol 16, 977-89.
4. Mohammadi, M. et al. (1991) Mol Cell Biol 11, 5068-78.
5. Larsson, H. et al. (1999) J Biol Chem 274, 25726-34.
6. Muh, S.J. et al. (2002) J Biol Chem 277, 50143-54.
7. Coutts, J.C. and Gallagher, J.T. (1995) Immunol Cell Biol 73, 584-9.
8. Jeftha, A. et al. (2004) J Clin Pediatr Dent 28, 173-6.
9. Wilkinson, C.C. et al. (2012) Childs Nerv Syst 28, 1221-6.
10. Slavotinek, A. et al. (2009) Am J Med Genet A 149A, 1814-7.
11. Katoh, M. (2009) J Invest Dermatol 129, 1861-7.

注意事项：

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM  NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C.  Do not aliquot the antibody.

*Species cross-reactivity is determined by western blot.

** Anti-rabbit secondary antibodies must be used to  detect this antibody.

Recommended Antibody Dilutions:

Western blotting 1:1000

Immunoprecipitation 1:50